Studies on new nicotinic acid ester derivatives. 6. Serum cholesterol level lowering effect of 2,2,6,6-tetrakis(nicotinoyloxymethyl) cyclohexanol (K-31).
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy; D002247:Carbon Isotopes; D002784:Cholesterol / Q000097:blood* / Q000378:metabolism; D003864:Depression, Chemical; D004952:Esters / Q000494:pharmacology; D007408:Intestinal Absorption / Q000187:drug effects; D008297:Male; D009539:Nicotinic Acids; D010743:Phospholipids / Q000097:blood; D010919:Placebos; D011817:Rabbits; D051381:Rats; D013897:Thoracic Duct / Q000601:surgery; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D002247:Carbon Isotopes; D004952:Esters; D009539:Nicotinic Acids; D010743:Phospholipids; D010919:Placebos; D014280:Triglycerides; D002784:Cholesterol